1. Home
  2. CMRC vs CHRS Comparison

CMRC vs CHRS Comparison

Compare CMRC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Commerce.com Inc.

CMRC

Commerce.com Inc.

HOLD

Current Price

$3.26

Market Cap

199.7M

Sector

N/A

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.14

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMRC
CHRS
Founded
2009
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
177.7M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
CMRC
CHRS
Price
$3.26
$1.14
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
$4.88
★ $5.51
AVG Volume (30 Days)
★ 1.2M
1.1M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
31.43
★ 472.00
EPS
★ 0.06
N/A
Revenue
★ $342,349,000.00
N/A
Revenue This Year
$5.11
$73.08
Revenue Next Year
$4.50
$30.94
P/E Ratio
$52.50
★ N/A
Revenue Growth
★ 2.83
N/A
52 Week Low
$1.95
$1.09
52 Week High
$5.55
$2.62

Technical Indicators

Market Signals
Indicator
CMRC
CHRS
Relative Strength Index (RSI) 59.01 37.82
Support Level $2.58 N/A
Resistance Level $3.39 $1.53
Average True Range (ATR) 0.21 0.09
MACD 0.00 -0.02
Stochastic Oscillator 64.42 0.00

Price Performance

Historical Comparison
CMRC
CHRS

About CMRC Commerce.com Inc.

Commerce.com Inc is engaged in offering a Software-as-a-Service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which the majority of its revenue is generated from Americas-U.S.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: